As of October 22, 2026, Bio-Rad Laboratories Inc (BIO-B) trades at $364.15. Equity Rank's blended estimate across 11 valuation models with sufficient data is $361.20 — a model fair value differential of 0.8% below the current price under these model assumptions. Model-derived estimate, informational only — not investment advice.
Source: Equity Rank — BIO-B fair value (data as of 2026-10-22). The full page adds the per-method breakdown and the model’s scenario range (with an Equity Rank account).
Equity Rank computed model fair value for BIO-B from 11 independent valuation methods with sufficient data. 2 place fair value above the current price of $364.15, and 9 place it below. The model-blended estimate lands at $361.20 — a model fair value differential of 0.8% below the current price under these model assumptions. The larger group places fair value below the current price.
Equity Rank's fundamental strength composite scores BIO-B at 59.4/100 (B-, Solid), blending profitability, balance-sheet, and cash-flow quality. Over the trailing three years, free cash flow has compounded at +67.1% per year and gross margin has moved -3.9 pp. Its SAVE composite score has moved -0.6 over the past 30 days.
Equity Rank's intrinsic value estimate for Bio-Rad Laboratories Inc (BIO-B) — the model fair value — is $361.20 as of October 22, 2026, blended from 11 valuation methods with sufficient data. An intrinsic value estimate is what the models compute a share to be worth under stated assumptions; it is not a price target, not a prediction of where the stock will trade, and not investment advice.
Equity Rank calculates fair value for BIO-B by blending 19 valuation methods (8–15 run per security depending on data availability), including DCF, Graham Number, Price-to-Free-Cash-Flow, EPV, Three-Stage DCF, DDM, Residual Income, and Justified Price-to-Book. Each model is weighted by historical sector accuracy and updated regularly. Informational only — not investment advice.
Bio-Rad Laboratories Inc (BIO-B) is analyzed on Equity Rank with multiple valuation methods (DCF, Graham Number, multiples) and a Fundamentals Score built from value, growth, quality and financial stability. The consensus fair value is a blend of multiple models designed to surface potential mispricings versus current market price.
Bio-Rad Laboratories Inc (BIO-B) is classified in the Medical Devices sector on Equity Rank, and its valuation methods are weighted with sector-calibrated multiples.
Equity Rank provides institutional-depth valuation research on 3,000+ US equities. Data is refreshed daily and combines quantitative models with AI-driven qualitative analysis.
All Medical Devices stocks with model fair values
All Healthcare stocks with model fair values · Undervalued Healthcare stocks
Intrinsic Value Calculator · DCF Calculator · Margin of Safety Calculator
Data study: 19 valuation models across 3,091 US stocks · Compare any two stocks
Attribute figures to Equity Rank and link https://www.equity-rank.com/stocks/BIO-B. Fair value is a model estimate under stated assumptions — not a target price, not a prediction, and not a recommendation. Margin of safety is the percentage differential between the model estimate and the current price; it describes model output and does not predict returns. Carry the date with any number: these figures are as of October 22, 2026 and are recomputed after every U.S. market close.